survival responses in a rat orthotopic glioma model (cure rates of 83%). We also highlighted the importance of the radioactivity activity gradient obtained by combining a simple injection (SI) with convection-enhanced delivery (CED). We assumed that the immune system played a role in the treatment's efficacy on account of the overproduction of peripheral cytokines, recruitment of immune cells to the tumor site, and memory response in long-term survivor animals. Hence, nanovectorized internal radiation therapy with activity gradients stimulating immune responses may represent a new and interesting alternative for the treatment of solid tumors such as glioblastomas.
INTRODUCTION
Glioblastomas (GBM) are the most common and lethal type of primary brain tumors [1] . Although surgery and external beam radiation therapy, with or without chemotherapy, slightly improve the prognosis, treatments are never curative [2] . Systemic toxicity, normal brain tissue sensitivity, and the blood-brain barrier (BBB) are the main factors responsible for treatment failure [3] .
Ionizing radiation is the gold-standard adjuvant treatment for malignant gliomas.
Given that, efforts in developing internal radiation have been made in order to prevent harm to healthy tissues. In this context, locoregional drug delivery modalities, such as stereotactic radiosurgery, which allow for blood-brain barrier (BBB) bypass and reduced systemic toxicity, are of major relevance. Clinical trials on GBM patients supported the usefulness of local radiolabeled peptide receptor therapy ( 90 Y-DOTATOC [4] ) and radioimmunotherapy ( 131 Itenascin antibodies [5] and 188 Re-nimotuzumab [6] ). Thus, nanoparticles issued from new technologies hold great promise for developing effective targeted therapies for gliomas. The distribution of the radionuclide will not only depend on its own intrinsic properties but also on those of the vector [7] . Hence, the benefit expected to come from loading the radionuclide is the avoidance of fast elimination after injection.
Colloidal drug carriers have been designed to incorporate radionuclides, such as lipid nanocapsules (LNC). These LNCs are synthesized through a phase inversion process without any organic solvent and consist of a lipid core surrounded by a tensioactive shell [8] . With biomimetic properties, they provide extensive drug encapsulation capacity [9] [10] [11] and exhibit biological effects such as P-gp inhibition [12] [13] [14] , endo-lysosomal escape [15] , and biological barrier crossing [15] . LNCs are implanted in brain tumors using stereotactic injections for inserm-00638699, version 1 -7 Nov 2011 locoregional therapy. We recently established the feasibility of this technique using 50nm-LNC loaded with a lipophilic complex of Rhenium-188 (LNC 188 Re-SSS -half-life: 16.9 hours; β -emitter: 2.12 MeV; γ emitter: 155 keV) for internal radiation therapy in malignant glioma, demonstrating a median survival of up to 45 days after a single injection of LNC 188 Re-SSS in an orthotopic 9L-glioma model [9] .
In order to optimize internal radiation strategy, we assessed the efficacy of repeated brain administrations of LNC 188 Re-SSS following 9L cell implantation. As simple stereotactic injections (SI) and convection-enhanced delivery (CED) lead to distinct LNC distribution volumes [16] , these two LNC 188 Re-SSS infusion techniques were chosen to study the impact of the activity gradient.
The current rationale of ionizing radiation is based on its ability to eradicate tumor cells, notably through excessive reactive oxygen species generation [17, 18] . Nevertheless, several lines of evidence have established that radiotherapy induces dose-dependent consequences such as adaptative responses, genomic instability, and abscopal effects [19] [20] [21] [22] [23] [24] . Hence, the recruitment and activation of biological effectors outside the treatment field, notably inflammatory and immune cells such as macrophages [20, [25] [26] [27] , dendritic cells [28] , or T cells, depend on the release of danger signals by irradiated tumor cells and the related microenvironment.
According to the fractionated internal radiotherapy protocol used in our study, different activity gradients may be applied in order to enhance different biologic responses.
In addition, synthetic nano-objects can also function as "danger signals" that activate dendritic cells, potentially inducing subsequent T-cell immunity [29] [30] [31] [32] . As gliomas are infiltrative tumors, any modification to the tumor microenvironment via ionizing radiation, with dichloromethane (1mL) and washed three times with 1mL of deionized water. The radiochemical purity (RCP) of the complex was checked by thin-layer chromatography as the ratio of migrated radioactivity to total radioactivity. Thin-layer chromatography was carried out using silica gel 60-F 254 alumina plates (Merck) and a solution of petroleum ether/dichloromethane (6/4; v/v) as an eluant. Radioactivity was assessed with a phosphorimaging machine (Packard, Cyclone storage phosphor system).
Nanocapsule formulation and characterization
The overall study was performed on 50nm diameter LNCs, which were prepared according to a phase-inversion process described by Heurtault et al. [8] . In brief, 25mg Lipoïd® S75-3, Bayer, Puteaux, France). Using a stereotactic head frame and a 10µL Hamilton syringe (Hamilton® glass syringe 700 series RN), 10µL of 1x10 3 9L cells were injected into the rat's right striatum. The coordinates used for the intracerebral injection were 1mm posterior to the bregma, 3mm lateral to the saggital suture (right hemisphere), and 5mm below the dura.
External beam radiation and groups.
An external beam radiation study was performed using a fractionated regimen of 2x8Gy at D6 and D12 following 9L cells implantation. Two groups were studied: a control group (n=6) and a treated one (n=8). We set the therapeutic dose at 16 Gy (2x8Gy) as the maximum tolerated dose (MTD) of 18 Gy (3x6Gy) proved to be effective in the 9L-glioma rat model [34] .
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Fractionated internal radiation, protocols, and groups A fractionated internal radiation study was performed at an early and late stage of tumor progression. In the first study, animals underwent internal radiotherapy with 2.8MBq of LNCs loaded with rhenium-188 (LNC 188 Re-SSS) on D6 and D12 following 9L cell implantation.
In the second study, the efficacy of LNC 188 Re-SSS was assessed at a late stage of tumor progression, and the animals therefore received internal radiotherapy on D12 and D18. Two We chose to set the injected activity at 2.8 MBq of LNC 188 Re-SSS because it proved to be effective after a single injection in the 9L-glioma model [9] .
Simple injection and convection enhancement delivery procedures
The animals were anesthetized with an intraperitoneal injection of 0.75-1.5mL/Kg of a solution containing 2/3 of ketamine (100mg/mL; Clorketam®, Vétoquinol, Lure, France) and 1/3 xylazine (20mg/mL; Rompun®, Bayer, Puteaux, France). For the SI, 10µL were injected inserm-00638699, version 1 -7 Nov 2011
into the rat striatum at a flow of 1µL/min using a 10µL syringe (Hamilton® glass syringe 700 series RN) with a 32-G needle (Hamilton ®). For this purpose, rats were immobilized in a stereotactic head frame (Lab Standard Stereotactic; Stoelting, Chicago, IL). Coordinates were 1mm posterior to the bregma, 3mm lateral to the saggital suture, and 5mm below the dura.
Following the injection, the needle was left in place for an additional 5 minutes to avoid expulsion of the suspension from the brain during the removal of the syringe.
CED injection was similar, except that the 10µL Hamilton® syringe with a 32-G needle was connected to a 100µL Hamilton ® 22-G syringe containing the product (Harvard Apparatus, Les Ulis, France) through a cannula (CoExTMPE/PVC tubing, Harvard Apparatus, Les Ulis, France). CED was performed using an osmotic pump PHD 2,000 infusion (Harvard Apparatus, Les Ulis, France) by controlling a 0.5µL/min rate for 2 hours.
Tissue distribution study
A tissue distribution study was carried out using 16 female Fisher rats 6 days following 9L implantation. They were divided into two groups: one injected with LNC 188 Re-SSS after a SI (n=8) and one with LNC 188 Re-SSS following a CED injection (n=8). In both groups, the animals were sacrificed at post-injection interval times of 24 hours (n=4) and 96 hours (n=4). The organs were removed, washed, and weighed (blood, liver, spleen, kidneys, heart, lung, stomach, small intestine, large intestine, bladder, bone, muscle, brain, and carcass). The content activity of each organ was determined using a gamma counter (Packard AutoGamma 5,000 series). 
Interleukin-2 (IL-2) and interferon-γ (IFN γ ) quantifications
Blood samples were collected from the tail vein using heparinized tubes in each protocol from a fractionated internal radiation study (D6/D12) at D8, D16, and D24 following 9L cell implantation. After centrifugation at 1 000g for 20 minutes, the rat IL-2 and rat IFN γ ELISA tests (Duoset, R&D Systems Europe, Lille, France) were immediately performed according to manufacturer's instructions.
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Immunohistochemistry Brains from tumor-bearing animals treated were frozen at D15, D24, and D32 in isopentane cooled by liquid nitrogen and stored at -80°C. Fourteen-micron cryosections were fixed with 4% of paraformaldehyde in phosphate-buffered saline 1X (pH=7.3) and washed three times with phosphate-buffered saline (PBS). In order to block nonspecific binding, sections were Rompun®, Bayer, Puteaux, France). The intracerebral tumor implantation procedure was described above, but the coordinates used were modified: 1mm posterior to the bregma, 3mm lateral to the saggital suture (left hemisphere), and 5mm below the dura.
Statistical analysis
Results are expressed as mean±standard deviation (SD). For the survival study, comparisons between control groups were made using the log-rank test (Mantel-Cox test). For other studies, statistical analysis was performed using the t test. Data was considered to be significant when p<0.05. This was corroborated by biodistribution studies, with 86% and 78% of the injected dose remaining in the brain 24 hours and 96 hours post-injection, respectively, regardless of the administration technique used (Figure 1d ).
Importance of the administration route on the activity gradient
To address the distribution of LNC 188 Re-SSS within the brain, autoradiography views were performed 24 hours after SI and CED injections (Figure 1e-g ). Even if biodistributions were similar using SI or CED injections, the distribution within the brain tissue itself revealed the rhenium-188 spread to be greater with CED than SI administrations, as illustrated by 2a-b) . Long-term survivors were defined as animals that survived for more than 120 days following 9L cell implantation [35] . Magnetic resonance imaging [36] 
Treatment efficacy of fractionated internal radiotherapy after tumor detection (D12/D18)
In order to mimic late-stage tumor progression, fractionated internal radiation was performed at D12 and D18 following 9L cell implantation. Protocols 3 and 4, which provided the best survival results during prior treatment, were used. As expected, no significant differences between the control groups were detected, with a median survival close to 28
days. However, with protocols 3 and 4, five out of six rats (83%) were long-term survivors (Figures 2f-g ). MRI confirmed these results, with a tumor lesion at D9 following 9L cell implantation, which grew up until D25 and then regressed, long-term survivor animals being free of brain tumors (Figure 2h ).
Effect of LNC 188 Re-SSS on the production of peripheral cytokines
As over-expression of interleukin-2 (IL-2) and interferon-γ (IFNγ) cytokines produced by T cells are important for anti-tumoral brain immune reponses [37] , these cytokines were quantified at D8, D16, and D24 in blood of control and LNC 188 Re-SSS-treated animals for (Figures 4a-b) .
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Rechallenge in long-term survivors reveals immune protection
To validate this immune response, long-term animal survivors obtained with protocols 3 and 4 were re-challenged with implantation of 1 000 9L cells in the left striatum.
Regardless of the fractionated internal radiation timing used (D6/D12, Figure 5a ; D12/D18, In this study, we evaluated fractionated internal radiation therapy using LNC 188 Re-SSS in an orthotopic 9L Fischer rat glioma model. Survival and immune-related effects induced by the variation in the 188 Re-activity gradient within the brain parenchyma were investigated.
The first part of this work highlights the advantages of using LNC for entrapping Rhenium-188 as physico-chemical properties of the nanocarrier prevail over those of Rhenium-188.
Hence, our data supported that most of rhenium-188 activity from LNC remained confined to the brain until its disintegration.
The originality of our strategy was to use two modes of stereotaxic injections during the fractionated treatment in order to modulate 188 Re distribution within the brain. Thus, a remarkable survival benefit was only revealed when SI injection was combined with CED, indicating that the 188 Re-activity gradient is of major significance. This therapeutic effect can be explained by the cellular heterogeneity and the related microenvironment of the tumor mass. Solid tumors are indeed heterogenous from a histology point of view with inflammatory infiltrates and vascular structures [40] . Different subpopulations of cancer cells are hierarchically and topographically organized, with radio-resistant cancer initiating cells [41] within either hypoxic or vascular niches [42] . Thus, we can assume that the injection of beam radiation used in this study triggered weaker therapeutic efficiency as compared with internal radiotherapy.
In this study, animals were treated with a combination of SI and CED at Days 6/12 and 12/18 following 9L cells implantation. As no significant differences were noted between early-and late-care of the tumor, tumor size and proliferation gradient did not appear to influence treatment response. This could be explained by a 188 Re-activity gradient that is sufficient for direct eradication of the entire tumor mass in the two situations (early-and late-care). In addition, the 188 Re-activity gradient might induce an indirect immune response likely to affect all types of tumor cells. Thus, we have investigated whether an adaptative immune response was involved in tumor regression. According to the scientific literature, radiation after external beam radiation exposure produces an immunogenic death of the most radiosensitive subset of cancer cells [43] . Recent evidence has highlighted the involvement of calreticulin and high-mobility group protein B1 (HMGB1) in the mechanism by which the irradiated tumor can become a source of antigen [19, 44] . Our data demonstrated that while there was a recruitment of immune cells with both internal and external radiotherapy, the intensity of this response was weaker after external than internal radiation. In addition, our internal radiation strategy induced a memory antitumor response as long-term survivors were partially or totally immunized after re-injecting 9L cells in contrast to naïve animals. As no long-term survivor animals were obtained with external beam radiation, the intensity of the immune response depending on the irradiation mode may play a role. Radiation has been reported to induce up-regulation of MCHI and other pro-immunogenic effects at the irradiated site [21, 45] . As MCHI expression was more important after internal radiotherapy compared with external radiation modality, we assume that tumor cell recognition by the inserm-00638699, version 1 -7 Nov 2011
immune system is improved in this context. Moreover, Dewan et al. have shown that two external radiation regimens had similar effects on tumor growth, but led to different synergistic effects when associated with immunotherapy [46] . The conditions of irradiation are of major significance, and the 188 Re-activity gradient used in our study may well play a role by enhancing a particular type of cell death (apoptosis, autophagy, or necrosis), thus leading to tumor eradication or not [47] .
The nano-object used for internal radiotherapy can interact with immune responses. As previously shown in scientific literature, the transporters associated with antigen processing (TAP) and multidrug resistance efflux pumps share a significant degree of homology among their transmembrane domains, which are thought to be the primary determinants of substrate specificity [48, 49] . As nanoparticles interfere with P-gp and reverse multidrug resistance in glioma cells [12] , they could promote pro-immunogenic conditions by increasing antigen processing based on interactions with TAP transporters. LNC may also cross biological barriers [12] with endo-lysosomal escape [15] , which may impact autophagy cell death [50] . This could be crucial as migrating glioblastoma cells have been shown to be resistant to apoptosis [50] . 
